Study of an injection for teens with allergies
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a new injection (JYB1904) that may help control allergic reactions. It is for teenagers aged 12 to 17 who have had allergic conditions, to see if the drug is safe and how it works in this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 17 years old.
- You must have a history of an allergic condition, like food allergies, hay fever, allergic asthma, or chronic hives.
- You must weigh at least 30 kilograms (about 66 pounds).
- If you are sexually active, you must agree to use effective birth control during the study and for one year after the last dose.
- You and your parent or guardian must sign a consent form and be willing to come to all study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational injection (called JYB1904) to see if it helps reduce allergy symptoms from dust mites, pet dander, and other indoor allergens. It is for adults with moderate to severe allergic rhinitis (hay fever) who still have symptoms despite using a daily nasal steroid spray.
This trial tests a new injectable medicine (JYB1904) to see if it can reduce itching and hives better than standard antihistamines alone. If you have chronic hives with no clear cause and still get symptoms despite taking antihistamines, this study may be an option for you.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This study tests a new medicine, MG-K10, given as an injection, to see if it can reduce eczema symptoms like itching and skin rash in teenagers. It's for teens whose eczema is not well controlled with topical treatments.
This early-phase trial is testing an experimental injection called JY231 for people with certain autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. The aim is to see if this treatment can reduce disease activity and improve symptoms.
This study tests a new injected medicine called SYH2092 in healthy adults. It aims to see how safe it is and how the body handles it, which could help develop a future treatment for conditions like diabetes or obesity.
Hear when a new Allergic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.